DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder

Information source: Astellas Pharma Inc
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Urinary Bladder, Overactive

Intervention: YM178 (Drug); Placebo (Drug); tolterodine (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Astellas Pharma Inc

Official(s) and/or principal investigator(s):
Use Central Contact, Study Chair, Affiliation: Astellas Pharma Inc

Summary

The purpose of the study is to evaluate the effect of YM178 in patients with overactive bladder for 12-week administration.

Clinical Details

Official title: Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Change from baseline in the mean number of micturitions per 24 hours

Secondary outcome:

Change from baseline in the mean number of urgency episodes per 24 hours

Change from baseline in the mean number of urinary incontinence episode per 24 hours

Change from baseline in the mean number of urge incontinence episodes per 24 hours

Change from baseline in the mean volume voided per micturition

Change from baseline in mean number of nocturia episodes

Change from baseline in domain score of quality of life scores as assessed by King's health questionnaire

Detailed description: This study examines the superiority of YM178 over the placebo and evaluates the safety and pharmacokinetics of YM178 in patients with overactive bladder, and to compare the efficacy and safety of YM178 over those of tolterodine, the control drug, without a non-inferiority test. The drug administration period is 14 weeks in total, consisting of 2 weeks for placebo (pre-investigation period) and 12 weeks for the investigational drug (treatment period).

Eligibility

Minimum age: 20 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patient with symptoms of overactive bladder for at least 24 weeks before initiation

of the pre-investigational period

- Patient capable of walking to the lavatory without assistance and measuring the urine

volume by him/herself

- Patient with an average frequency of micturition of 8 or more times per 24-hour

period

- Written informed consent has been obtained

Exclusion Criteria:

- Patients without experience of urge incontinence before informed consent

- Patients given a clear diagnosis of stress incontinence

- Patients with transient symptoms suspected of overactive bladder (drug induced,

psychogenic, etc)

- Patients complicated with urinary tract infection, urinary stones, and/or

interstitial cystitis

- Patients with a previous history of recurrent urinary tract infection

- Patients complicated with or with a history of bladder tumor or prostatic tumor

- Patients confirmed to have a post-void residual volume of ≥ 100 mL or with a

clinically significant lower urinary tract obstructive disease

- Patients given medication for the treatment of lower urinary tract obstructive

disease within 4 weeks before the pre-investigational period

- Patients with an indwelling catheter or practicing intermittent self-catheterization

- Patients given radiotherapy influencing urethral functions, or thermotherapy for

benign prostatic hyperplasia

- Patients given surgical therapy which may influence urethral functions within 24

weeks before the pre-investigational period

- Patients with uncontrolled hypertension or with a pulse rate ≥ 110 bpm or < 50 bpm

- Patients with polyuria exceeding 3000 mL in mean daily urine volume

- Patients meeting any of the following in the examinations

- Patients with abnormal electrocardiogram judged inappropriate as subjects by the

ECG Evaluation Committee

- Patients with AST (GOT) or ALT (GPT) 2. 5 times higher than the upper limit of

the normal range (or 100 IU/L)

- Patients with a blood creatinine level ≥ 2. 0 mg/dL

Locations and Contacts

Chubu, Japan

Kantou, Japan

Kinki, Japan

Kyushu, Japan

Additional Information

Link to Results on JAPIC

Starting date: July 2009
Last updated: July 15, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017